Financial Performance - GAAP diluted earnings per share (EPS) of 0.44,up122942.6 million, with CooperVision revenue up 8% to 635.9millionandCooperSurgicalrevenueup6306.7 million[9] - Operating margin of 17%, compared to 11% in last year's second quarter; non-GAAP operating margin remained at 24%[11] - Non-GAAP net income for the quarter was 169.5million,or0.85 per share, compared to 153.5million,or0.77 per share, in the prior year[21] - Net income for the quarter was 88.9million,comparedto39.8 million in the prior year, resulting in diluted earnings per share of 0.44,upfrom0.20[1] - Non-GAAP diluted EPS increased by 0.08to0.85, a 10% rise compared to the same quarter last year[64] Revenue Guidance - The company raised its fiscal year 2024 financial guidance to a non-GAAP diluted EPS of 3.54−3.60[7] - CooperSurgical revenue guidance for fiscal year 2024 is set at 1,272−1,292 million, indicating organic growth of 5% to 7%[15] - The company expects total revenue for fiscal 2024 to be between 3,863millionand3,905 million, with organic growth projected at 7.5% to 8.5%[39] - CooperVision expects revenue guidance of 2,591−2,613 million, indicating organic growth of 8.5% to 9.5%[69] Operational Efficiency - Operating income increased to 161.7million,upfrom96.3 million in the same quarter last year, indicating improved operational efficiency[1] - Cash provided by operations was 111.0million,resultinginfreecashflowof36.9 million after capital expenditures of 74.1million[12]−Non−GAAPoperatingincomeforthethreemonthswas224.8 million, representing a 24% margin, consistent with the prior year[44] Revenue Breakdown - CooperVision's total revenue of 635.9millionincludeda12264.4 million, up 9% year-over-year, while EMEA revenue was 237.0million,up13635.9 million, with organic growth of 11% and a currency impact of 2%[58] - CooperSurgical revenue was 306.7million,showingan84,243.5 million, while stockholders' equity rose to 7,803.9million[30]−Totalassetsreached12,047.4 million, an increase from 11,658.9millionasofOctober31,2023[60]−Thecompanyhastotaldebtof2.7 billion, with cash and cash equivalents at 112.4million[66]−Currentassetstotaled1,859.0 million, up from 1,704.9millioninthepreviousperiod[60]−Goodwillincreasedto3,761.3 million from 3,624.5million,reflectingongoingacquisitions[60]ResearchandDevelopment−Researchanddevelopmentexpensesincreasedto38.9 million from 32.6millionyear−over−year,highlightingthecompany′scommitmenttoinnovation[1]CostManagement−Thecompanyisfocusedonstrategicacquisitionsandoptimizingitscoststructuretoenhanceoverallperformance[40]GrossProfitandMargin−Thecompanyreportedagrossprofitof631.2 million, representing a gross margin of 67%[19] - Gross profit for the same period was 631.2million,comparedto582.9 million in the prior year, reflecting a strong performance[1] - Gross margin improved to 67%, up from 66% in the previous year[65]